What cancer does Lorlatinib treat?

Lorlatinib (Lorlatinib) is a targeted anti-cancer drug, used to treat non-small cell lung cancer with anaplastic lymphoma kinase (ALK) gene alteration. It is also called ALK-positive non-small cell lung cancer. Demonstrated clinical activity in patients of all ages harboring three neuroblastoma-specific hotspotsALK mutations, including those previously treated with other ALK inhibitors Patients who previously receivedALK-targeted agents may need to receive lorlatinib for non-small cell lung cancer if their cancer has begun to grow again (worse). It is the only ALK inhibitor with meaningful activity against the ALK G1202R mutation in lung cancer.